RPT-INSIGHT-How Pfizer has shifted U.S. profits overseas for years

RPT-INSIGHT-How Pfizer has shifted U.S. profits overseas for years

Pfizer and Allergan are in talks to create the world’s biggest drug company by market value. The problem with this scenario? Pfizer’s take over of Allergan have faced a political backlash in the United States over fears that the deal would lead to the company shifting its headquarters and taxable profits to Ireland. But a Reuters…

Bloomberg.com logo

Cancer Doctors Join Insurers in U.S. Drug-Cost Revolt

Bloomberg reports on how the backlash over surging drug prices is starting to take hold. With the average cost of branded cancer drugs doubling over the past decade to about $10,000 per month in the U.S., doctors, insurers and politicians are all moving in different directions to pressure drug-makers on pricing. Cancer doctors, in particular,…

The Economist Logo

Health and appiness

The Economist reports: Those pouring money into health-related mobile gadgets and apps believe they can work the miracle of making health care both better and cheaper. From this perspective, happiness is equated to “appiness”, meaning the opportunities created by combining health and technological applications. The promise of technologically-altered healthcare systems could pave the way to…

Mass Spectrometry Is Moving To Point-of-Care: Why This Matters To You

Breaking Down Mass Spectrometry For many of you reading this article, the words mass spectrometry will probably mean nothing. However, in the growing field of healthcare and clinical diagnostics, it is an ever increasing term used in the medical lexicon. Mass Spectrometry is an analytical chemistry technique that has been around commercially since the 1950’s,…

INSIGHT- Profit bonanza eludes companies chasing obesity business

INSIGHT- Profit bonanza eludes companies chasing obesity business

Reuters reports that soaring diabetes rates, driven by increasing obesity, have fuelled profits at the Danish company, Novo Nordisk’s Kalundborg factory for nearly two decades. Now, the company wants to tackle obesity head on by launching a specific treatment. At first thought, it seems to be a no-brainer. However, in a global economic downturn, modestly effective weight-loss…

Insight: How new cancer drugs can skip randomized trials

Insight: How new cancer drugs can skip randomized trials

Back in 2006 when doctors started testing a melanoma treatment on chemotherapy patients with the hopes of shrinking tumors – they were used to facing slim odds. But now, a new drug called Zelboraf that targets specific mutations in cancer cells, is helping them beat those odds by showing signs of significant tumor shrinkage. These Zelboraf research tests,…